Nyxoah Appoints Scott Holstine as Chief Commercial Officer

EQS-News: Nyxoah SA. / Key word(s): Personnel
Nyxoah Appoints Scott Holstine as Chief Commercial Officer

15.07.2024 / 08:15 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Nyxoah Appoints Scott Holstine as Chief Commercial Officer

Mont-Saint-Guibert, Belgium - July 15, 2024, 8:00am CET / 2:00am ET - Nyxoah
SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical
technology company focused on the development and commercialization of
innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced
the appointment of Scott Holstine as Chief Commercial Officer. In this role,
Scott will lead the commercial operations of Nyxoah enabling a successful
U.S. launch.

Scott brings over 26 years of experience in the medical device industry with
a proven track record in U.S. product launches, building and leading
commercial organizations trademarked by strong operational execution. Scott
is a passionate advocate for people and talent development. Scott graduated
with the Superintendent's Award for Excellence (Star Wreath) from the United
States Military Academy at West Point, NY. After serving as a Captain in the
U.S. Army, Scott received his MBA from the University of Minnesota, Carlson
School of Management - Minneapolis, MN.

"As we expect FDA approval by the end of 2024, the hiring of an experienced
commercial leader is instrumental in further accelerating our U.S.
go-to-market strategy into a concrete launch execution plan. This starts
with having a commercial team fully operational by year-end. Scott is a
dynamic and creative leader with countless accomplishments in building
high-performing teams and developing new markets for innovative
technologies," commented Olivier Taelman, Nyxoah Chief Executive Officer.
"This appointment is the kickoff of building a team of world-class patient-
and clinician-focused professionals, supporting Nyxoah's mission to make
sleep simple again for OSA patients."

"This is a promising time for patients with OSA. Nyxoah's strong DREAM study
results and Genio's success in markets outside of the U.S. have demonstrated
the potential of Genio's breakthrough and unique solution. Both patients and
physicians are eagerly awaiting a second player in the HGNS field. I am
thrilled to be part of the team building out a patient-focused commercial
operation that prioritizes the success of our healthcare provider partners
in treating OSA," added Scott.

About Nyxoah

Nyxoah is a medical technology company focused on the development and
commercialization of innovative solutions to treat Obstructive Sleep Apnea
(OSA). Nyxoah's lead solution is the Genio® system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for OSA, the
world's most common sleep disordered breathing condition that is associated
with increased mortality risk and cardiovascular comorbidities. Nyxoah is
driven by the vision that OSA patients should enjoy restful nights and feel
enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio®
system received its European CE Mark in 2019. Nyxoah completed two
successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July
2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah
received CE mark approval for the expansion of its therapeutic indications
to Complete Concentric Collapse (CCC) 2 patients, currently contraindicated
in competitors' therapy. Additionally, the Company announced positive
outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization
approval.

For more information, please see the Company's annual report for the
financial year 2023 and visit http://www.nyxoah.com/.

Caution - CE marked since 2019. Investigational device in the United States.
Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect the Company's or, as appropriate, the Company
directors' or managements' current expectations regarding the entry into of
the loan facility agreement and the synthetic warrant agreement with the
EIB; the use of proceeds from the loan facility agreement; the Genio® system
and ongoing clinical studies of the Genio® system; the potential advantages
of the Genio® system; Nyxoah's goals with respect to the development,
regulatory pathway and potential use of the Genio® system; the utility of
clinical data in potentially obtaining FDA approval of the Genio® system;
reporting data from Nyxoah's DREAM U.S. pivotal trial; filing for FDA
approval; and entrance to the U.S. market. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions and other
factors that could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These risks,
uncertainties, assumptions and factors could adversely affect the outcome
and financial effects of the plans and events described herein.
Additionally, these risks and uncertainties include, but are not limited to,
the risks and uncertainties set forth in the "Risk Factors" section of the
Company's Annual Report on Form 20-F for the year ended December 31, 2023,
filed with the Securities and Exchange Commission ("SEC") on March 20, 2024,
and subsequent reports that the Company files with the SEC. A multitude of
factors including, but not limited to, changes in demand, competition and
technology, can cause actual events, performance or results to differ
significantly from any anticipated development. Forward looking statements
contained in this press release regarding past trends or activities are not
guarantees of future performance and should not be taken as a representation
that such trends or activities will continue in the future. In addition,
even if actual results or developments are consistent with the
forward-looking statements contained in this press release, those results or
developments may not be indicative of results or developments in future
periods. No representations and warranties are made as to the accuracy or
fairness of such forward-looking statements. As a result, the Company
expressly disclaims any obligation or undertaking to release any updates or
revisions to any forward-looking statements in this press release as a
result of any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking statements are
based, except if specifically required to do so by law or regulation.
Neither the Company nor its advisers or representatives nor any of its
subsidiary undertakings or any such person's officers or employees
guarantees that the assumptions underlying such forward-looking statements
are free from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained 3 in this press
release or the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak only as
of the date of this press release.

Contact:

Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

For Media

Belgium/France
Backstage Communication - Gunther De Backer
gunther@backstagecom.be

International/Germany
MC Services - Anne Hennecke
anne.hennecke@mc-services.eu


---------------------------------------------------------------------------

15.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Nyxoah SA.
                   Rue Edouard Belin 12
                   1435 Mont-Saint-Guibert
                   Belgium
   E-mail:         info@nyxoah.com
   Internet:       www.nyxoah.com
   ISIN:           BE0974358906
   WKN:            A2QCWK
   Listed:         Regulated Unofficial Market in Dusseldorf, Frankfurt,
                   Munich, Stuttgart
   EQS News ID:    1945745

End of News EQS News Service
---------------------------------------------------------------------------

1945745 15.07.2024 CET/CEST